没有幻灯片标题-m.pptVIP

Anistreplase(阿尼普酶) It is a streptokinase-plasminogen complex, in which lys-plasminogen is acylated at its catalyicsite serine. The acyl group is hydrolyzed in vivo, allowing the complex to bind to fibrin prior to activation, and this modification confers some specificity toward clots on the fibrinolytic process. It is used coronary thrombolysis also. Fibrinolytic drugs Adverse effects The thrombolytic agents do not distinguish between the fibrin of an unwanted thrombus and the fibrin of a beneficial hemostatic plug. Hemorrhage is a major side effect. Antidotes: fibrinolytic inhibitors (PAMBA氨甲苯酸, AMCHA氨甲环酸) Part 4. Hemostatic drugs (Haemostats, 促凝血药, 止血药) Vitamin K 1. Carboxylation of the glutamic acid residues of II, VII, IX, X, protein C. 2. To prevent bleeding with vitamin K deficiency. 3. Response to vitamin K is slow, the severe hemostasis patients should be infused with fresh plasma imme-diately. Thrombin-like agents (凝血酶制剂) Thrombin(凝血酶, factor Ⅱ) Prothrombin complex(凝血酶原复合物, factor Ⅱ、Ⅶ、Ⅸ、Ⅹ) used for various bleeding. Globulin anti-hemophilia (factor Ⅷ, 抗血友病球蛋白) used for treatment for hemophilia. Haemostats Drugs preventing activation of antifibrinolytics aprotinin (抑肽酶） tranexamic acid (AMCHA, 氨甲环酸) p-aminomethylbenzoic acide (PAMBA, 氨甲苯酸） used for preventing the activation fibrinolysis and resultant bleeding Haemostats Inhibiting plasminogen activation Part 5. Antianemic drugs 抗贫血药 1. Cause of anemia: (1)Anemia may result from the excess destruction of erythrocytes; (2)Anemia may result from nutritional deficiencies, including: iron, minerals, vitamins (B12 and folic acid), ascorbic acid, riboflavin, etc. 2. Drugs for treatment of anemia: Iron preparations; Folic acid and vitamin B12; Erythropoietin(EPO), and rhEPO (Reconbanant human EPO) Iron preparations(铁制剂) Ferrous sulfate(硫酸亚铁), Ferric ammonium citrate(枸橼酸铁铵) Iron dextran(右旋糖酐铁), Iron s